Day 1 - Saturday, 9 June 2018
Topics
Meeting category
Date(s)
9 Jun 2018 - 10 Jun 2018
Location
Beijing,
China
Organizer
Titanium Level Support
Sponsor logos
Asian Conference on Hepatitis and AIDS (ACHA) 2018
Related Enduring Materials
Enduring Materials
- 09:00
09:00
Opening words
Jiahong Dong, MD, PhD
Beijing Tsinghua Changgung Hospital
Session 1: Clinical management of HIV -
Chairs
Charles Boucher, MD, PhD
Erasmus Medical Center, the Netherlands
Fujie Zhang, MD, PhD
Beijing Ditan Hospita
09:15
Do we still need PIs for HIV therapy?
09:45
Reaching 90-90-90 and beyond
Session 2: HIV Eradication - Is it possible? -
Chairs
Nicholas Paton, MD, FRCP
National University of Singapore, Singapore
Hongxin Zhao, MD, MPH
Beijing Ditan Hospital, Capital Medical University, China
11:15
Identification and eradication of HIV tissue reservoirs in a nonhuman primate model
Binhua Ling, MD, PhD
Tulane National Primate Research Center, Tulane University School of Medicine, USA
11:40
Eradication of HIV
12:05
A clinical trial of HIV functional cure based on a novel type of RNA interference technique
Gilead Sciences-sponsored symposium: Optimizing management of HIV/HCV co-infection and HIV/ HBV coinfection in China - 13:45
13:45
Welcome and Introduction
13:50
Management HIV/HBV coinfection in China
Hao Wu, MD, PhD
Beijing You’an Hospital
14:10
Management HIV/HCV coinfection in China
14:30
Panel Discussion: Overcoming challenges in coinfection management in China
Session 3: Hepatology -
Chairs
Zhongping Duan, MD, PhD
Beijing You’an Hospital
14:45
Living donor liver transplantation for hepatitis virus related liver diseases
15:10
Prevention of recurrent hepatitis B after liver transplantation
Chung Mau Lo, BBS, JP, MBBS, MS, FRCS, FRACS, FACS, FHKAM (Surgery), FCSHK
University of Hong Kong
15:35
Constructing the paradigm for the precision hepatobiliary surgery
Jiahong Dong, MD, PhD
Beijing Tsinghua Changgung Hospital
Session 4: Public Health: Elimination Approaches of Viral Hepatitis -
Chairs
Bonaventura Clotet, MD, PhD
Hospital Universitari “Germans Trias I Pujol”, Spain
Wei Lai, MD
Peking University People’s Hospital
16:45
Elimination of viral hepatitis: Global perspective
17:10
Elimination of viral hepatitis: Chinese perspective
Zijian Feng, MD, MPH
China CDC
Day 2 - Sunday, 10 June 2018
Session 5: HBV - 09:00
09:00
Progress on HBV treatment
Hao Wu, MD, PhD
Beijing You’an Hospital
Hong Ren
-
08:30
Treatment of CHB in China: Experience and evidence from real-world studies
08:50
Non-viral liver diseases in China
09:10
CHB treatment with Chinese medicine and NAs
Chairs
Jidong Jia, MD, PhD
Beijing Friendship Hospital, Capital Medical University
Chung Mau Lo, BBS, JP, MBBS, MS, FRCS, FRACS, FACS, FHKAM (Surgery), FCSHK
University of Hong Kong
10:10
New indicators for the evaluation of hepatitis B therapy
10:30
Guidelines on the management of ascites and complications in cirrhosis
Xiaoyuan Xu, MD, PhD
Peking University First Hospital
10:50
Antiviral therapy for post-transplant liver disease
Yuan Huang, MD, PhD
Beijing Tsinghua Changgung Hospital
Gilead Sciences-sponsored symposium: HCV: From simlification to elimination -
Chair
Hui Zhuang
Peking University Health Science Center
11:20
From simlification to elimination
Wen Xie, MD
Beijing Ditan Hospital, Capital Medical University
Special session: Introduction of MDT model of Beijing Tsinghua Changgung Hospital -
Chairs
Hui Zhuang
Peking University Health Science Center
Zhongping Duan, MD, PhD
Beijing You’an Hospital
Introduction of MDT model of Beijing Tsinghua Changgung Hospital
Jiahong Dong, MD, PhD
Beijing Tsinghua Changgung Hospital
Session 6: HCV -
Chair
Yuan Huang, MD, PhD
Beijing Tsinghua Changgung Hospital
13:30
New treatment options for HCV in China
Wei Lai, MD
Peking University People's Hospital, China
13:50
DAA Single center clinical data analysis
Wen Xie, MD
Beijing Ditan Hospital, Capital Medical University
14:10
Treatment strategies for HBV/HCV co-infection
Guofeng Chen, MD, PhD
Beijing 302 Hospital
14:30
Abstract presentations
Efficacy and tolerability of grazoprevir and elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV and HIV co-infection: A nonrandomised, open-label clinical trial
Chien-Yu Cheng
HIV-1/HCV co-infection treatment with single-tablet antiviral regimens (CoSTARs): 12 Weeks of Ledipasvir/ Sofosbuvir (LDV/SOF) after randomized switch to Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (E/C/F/TAF) or rilpivirine/F/TAF (R/F/TA
Damian Mccoll
Session 7: Co-infection -
Chairs
Jiahong Dong
Beijing Friendship Hospital, Capital Medical University, China
Hui Zhuang
Peking University Health Science Center
15:45
Transmission bottlenecks of HIV and HCV, and their impacts on prevention strategies
Yiming Shao, MD, PhD
China CDC
16:05
Sequential cross-section study on hepatitis viruses infection in Chinese AIDS patients
16:25
Non-alcoholic fatty liver disease in China
17:00
Closing remarks
Hui Zhuang
Peking University Health Science Center
Overview
Welcome
The very successful 7th Asian Conference on Hepatitis and AIDS (ACHA) took place from 9 - 10 June 2018 in Beijing, China.
The Organizing Committee would like to thank all invited speakers and participants for their contribution to this workshop!
We would like to thank our supporters:Gilead Science and AbbVie for making this event possible.
General Information
Unique Features
- A program with a special focus on the needs in China and Asia
- A true scientific platform for local and regional clinicians and clinical researchers to present their data
- A unique opportunity for regional clinicians, researchers, and pharmaceutical companies to meet and collaborate
- A true scientific platform for local and regional clinicians and clinical researchers to present their data
- A unique opportunity for regional clinicians, researchers, and pharmaceutical companies to meet and collaborate
Meeting Objectives
This meeting aims to:
- Provide education on the latest treatment options for HBV, HCV, HIV and associated co-infections
- Present the latest research data, especially in the Asian context and translate knowledge into clinical practice
- Provide a platform for interaction and dialogue among different disciplines and facilitate collaborations among local, national and regional communities
- Provide education on the latest treatment options for HBV, HCV, HIV and associated co-infections
- Present the latest research data, especially in the Asian context and translate knowledge into clinical practice
- Provide a platform for interaction and dialogue among different disciplines and facilitate collaborations among local, national and regional communities
Learning Objectives
After participating in this activity, participants will be able to:
- Summarize the most recent results in drug development (including most recent clinical trial results) for HBV, HCV, and HIV
- Integrate the latest scientific results into daily clinical care to improve the treatment quality for HBV, HCV and HIV-positive individuals
- Summarize the most recent results in drug development (including most recent clinical trial results) for HBV, HCV, and HIV
- Integrate the latest scientific results into daily clinical care to improve the treatment quality for HBV, HCV and HIV-positive individuals
Practical Information
Disclaimer
This conference is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this conference, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this conference. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the conference.
Liability and insurance
By registering for the conference participants agree that the organizers do not accept responsibility for medical-, travel- or personal insurance. Participants are advised to take out their own insurance policies.
Support
Endorsers
Language
Related Programs
